3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

M2i Group Roflumilast

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers, 13 USDMF, 6 EU WC, 5 KDMF, 10 NDC API, 19 Listed Suppliers, $ API Reference Price

28 API Suppliers
13 USDMF
6 EU WC
5 KDMF
10 NDC API
19 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

84 Drugs in Development

84 Drugs in Development

INTERMEDIATES

6 Intermediate Suppliers

6 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

49 FDF Dossiers, 24 FDA Orange Book, 14 Europe, 3 Canada, 1 South Africa, 7 Listed Dossiers

49 FDF Dossiers
24 FDA Orange Book
14 Europe
3 Canada
1 South Africa
7 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 250MCG, TABLET;ORAL - 500MCG

TABLET;ORAL - 250MCG
TABLET;ORAL - 500MCG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma, 4 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 9 BASF, 2 DFE Pharma, 1 Gangwal Chemicals, 2 Ingredion Pharma Solutions, 15 Kerry, 8 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Prachin Chemical, 6 Roquette, 1 Seppic, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Sigachi Industries, 1 Vasa Pharmachem

3 SPI Pharma
4 Faran Shimi Pharmaceutical
1 Boai NKY Pharmaceuticals Ltd
2 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
9 BASF
2 DFE Pharma
1 Gangwal Chemicals
2 Ingredion Pharma Solutions
15 Kerry
8 Microlex e.U
1 Novo Excipients
1 Pharmatrans-Sanaq
4 Pluviaendo
1 Prachin Chemical
6 Roquette
1 Seppic
2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
2 Sigachi Industries
1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

41 Fillers, Diluents & Binders, 11 Direct Compression, 10 Granulation, 8 Lubricants & Glidants, 6 Solubilizers, 5 Co-Processed Excipients, 4 Disintegrants & Superdisintegrants, 4 Controlled & Modified Release, 3 Chewable & Orodispersible Aids, 3 Thickeners and Stabilizers, 3 Taste Masking, 3 Parenteral, 2 Coating Systems & Additives, 1 Emulsifying Agents, 1 Film Formers & Plasticizers

41 Fillers, Diluents & Binders
11 Direct Compression
10 Granulation
8 Lubricants & Glidants
6 Solubilizers
5 Co-Processed Excipients
4 Disintegrants & Superdisintegrants
4 Controlled & Modified Release
3 Chewable & Orodispersible Aids
3 Thickeners and Stabilizers
3 Taste Masking
3 Parenteral
2 Coating Systems & Additives
1 Emulsifying Agents
1 Film Formers & Plasticizers

DIGITAL CONTENT

94 NEWS #PharmaBuzz

94 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 13 Finished Drug Prices, 10 Annual Reports

2 US Medicaid Prescriptions
13 Finished Drug Prices
10 Annual Reports

MARKET PLACE

14 APIs, 1 FDF Dossiers

14 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

45 US Patents, 4 US Exclusivities, 4 Health Canada Patents

45 US Patents
4 US Exclusivities
4 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 Others

5 Others

$ API Ref.Price (USD/KG) : 158,313 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4AstraZeneca Canada Inc.

filter Patent Reset all filters

4 All

01 12165192

02 12475923

03 12506956

04 12506962

filter Product Reset all filters

4 All

01 4Roflumilast

filter Dosage Reset all filters

4 All

01 4Tablet

filter Exp Date Reset all filters

4 All

01 12014-07-02

02 12023-02-19

03 22023-11-26

Product Main Page

01

AstraZeneca Canada Inc.

Roflumilast

Biotech Digital Meet

Not Confirmed

AstraZeneca Canada Inc.

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-02-19

Date Granted : 2013-06-18

Roflumilast

Brand Name : DAXAS

Patent Number : 2475923

Filing Date : 2003-02-19

Strength per Unit : 500?g

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2023-02-19

Date Granted : 2013-06-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

AstraZeneca Canada Inc.

Roflumilast

Biotech Digital Meet

Not Confirmed

AstraZeneca Canada Inc.

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2014-07-02

Date Granted : 2001-04-24

Roflumilast

Brand Name : DAXAS

Patent Number : 2165192

Filing Date : 1994-07-02

Strength per Unit : 500?g

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2014-07-02

Date Granted : 2001-04-24

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

AstraZeneca Canada Inc.

Roflumilast

Biotech Digital Meet

Not Confirmed

AstraZeneca Canada Inc.

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-11-26

Date Granted : 2012-01-03

Roflumilast

Brand Name : DAXAS

Patent Number : 2506962

Filing Date : 2003-11-26

Strength per Unit : 500?g

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2023-11-26

Date Granted : 2012-01-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

AstraZeneca Canada Inc.

Roflumilast

Biotech Digital Meet

Not Confirmed

AstraZeneca Canada Inc.

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-11-26

Date Granted : 2012-10-02

Roflumilast

Brand Name : DAXAS

Patent Number : 2506956

Filing Date : 2003-11-26

Strength per Unit : 500?g

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2023-11-26

Date Granted : 2012-10-02

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!